GSK Looks To Capitalize On AstraZeneca’s Anemia Drug Knock-Back
Safety Profile Will Be Battleground
AstraZeneca and FibroGen hit another safety roadblock with roxadustat, while GSK is hoping it might catch up with its rivals in the US.
You may also be interested in...
The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.
While demand for Shingrix is expected to return in the US, the slow process of COVID-19 vaccination in many other countries will delay its uptake.
In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.